Abstract

BackgroundRecently, the development of drug delivery which delivers controlled drug release at the tumor sites emerged as an attractive option for enhancing anticancer therapeutics. Next-generation nanotherapeutics must not contain only the nanoscale but should find their way to the solid tumor via active or passive targeting. Surface modification by pegylated lipids is one of the approaches used to made liposomes long-circulating and passively target the tumor. Pegylation of liposomes help them to alter the pharmacokinetics of drug molecule in vivo. The successful journey of such a complex drug delivery system from bench to clinic requires in-depth understanding and characterization. In this research, we fabricated and characterized sterically stabilized liposomes of topotecan which meets the clinical need. Liposomes have been prepared using ethanol injection-solvent evaporation method followed by extrusion for size reduction. Outer medium was replaced with an isotonic sucrose solution using dialysis followed by drug loading. We characterized liposomes’ membrane phase and dynamics, drug and lipid quantification, size distribution, state of encapsulated drug, internal volume and internal pH of liposomes, presence, and thickness of grafted PEG on the liposomes surface, and in vitro leakage test.ResultsAll these studied parameters directly or indirectly provide information regarding the pharmacokinetic behavior of the formulation and the tumor-targeting property of the drugs in vivo. We encapsulated the topotecan in nanoliposomes with pegylation on the surface resulting in long-circulating stealth liposomes. Nanoliposomes remotely loaded with topotecan by transmembrane gradient method.ConclusionOur in vitro characterization of topotecan liposomes provides an explanation for the good therapeutic efficacy of tumor cells.

Highlights

  • The development of drug delivery which delivers controlled drug release at the tumor sites emerged as an attractive option for enhancing anticancer therapeutics

  • Limitations of small molecule chemotherapeutics The efficacy of currently available anticancer agents is mainly compromised due to their drawbacks like poor solubility, poor bioavailability, lack of selectivity for normal and cancer cells resulted in toxicity

  • As the pharmacokinetic property of drugs will be decided by the carrier system, longer circulation and high drug loading capacity can be achieved by changing the different physicochemical properties of the carrier system

Read more

Summary

Introduction

The development of drug delivery which delivers controlled drug release at the tumor sites emerged as an attractive option for enhancing anticancer therapeutics. Patel and Patel Future Journal of Pharmaceutical Sciences (2020) 6:79 body cells that are in the growing stage like bone marrow and digestive tissues are getting affected and causing most side effects associate with anti-cancer agents To overcome these side effects, one of the alternatives is to change the molecule to its salt form or slight modification in the chemical moiety. As the pharmacokinetic property of drugs will be decided by the carrier system, longer circulation and high drug loading capacity can be achieved by changing the different physicochemical properties of the carrier system These carrier systems offer an advantage of passive targeting of a molecule to the tumor site by the mechanism known as enhanced permeation and retention effect (EPR). Normal tissue contains tight junctions between the blood capillary cells, so preventing macromolecules but small molecules to enter in normal tissue leads to poor tumor targeting and systemic toxicities

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call